(INNS)
CAMRELIZUMAB(SLE)
KAMRELIZUMAB(INNC)
IMMUNOGLOBULIN G4-KAPPA, ANTI-[HOMO SAPIENSPDCD1 (PROGRAMMED CELL DEATH 1, PD-1, PD1,CD279)], HUMANIZED MONOCLONAL ANTIBODY; GAMMA4 HEAVY CHAIN (1-443) [HUMANIZED VH (HOMO SAPIENS IGHV3-7*01 (90.80%) -(IGHD) -IGHJ4*01) [8.8.9] (1-116) -IGHG4*01 (CH1 (117-214), HINGE S10>P (224) (215-226), CH2 (227-336), CH3 (337-441), CHS (442- 443)) (117-443)], (130-214')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-214') [HUMANIZED V-KAPPA (HOMO SAPIENS IGKV1- 39*01 (87.40%) -IGKJ1*01) [6.3.9] (1'-107') -HOMO SAPIENS IGKC*01, KM3 (108'-214')]; DIMER (222-222":225-225")- BISDISULFIDE, RECOMMENDED INN: LIST 77(WHO)
CAMRELIZUMABUM(INN)